Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison

Published:2022-06 Issue:3 Volume:20 Page:285-295
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Santoni Matteo^ORCID,Aurilio Gaetano,Massari Francesco,Grande Enrique,Matrana Marc R,Rizzo Mimma,De Giorgi Ugo,Incorvaia Lorena^ORCID,Martignetti Angelo,Molina-Cerrillo Javier^ORCID,Zabalza Ignacio Ortego,Mollica Veronica,Rizzo Alessandro^ORCID,Battelli Nicola,Porta Camillo^ORCID

Funder

AstraZeneca

Alexion Pharmaceuticals

Pfizer

Astellas Pharma US

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2019

2. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: Renal, Penile, and Testicular Tumours;Moch;Eur Urol,2016

3. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries;Allemani;Lancet,2018

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma;Motzer;N Engl J Med,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update;Journal of Cancer Research and Clinical Oncology;2024-04-09

2. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence;Clinical Genitourinary Cancer;2023-11

3. An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines;International Journal of Molecular Sciences;2023-03-15

4. Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting;Cancer Medicine;2023-02-10

5. Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors;Cancer Drug Resistance;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3